TY - THES A1 - Grän, Franziska T1 - Rezeptor-vermittelte Chemotherapie von ovarialen Karzinomzellen mit Disorazol-GnRH-Konjugaten T1 - Targeted therapy of ovarian cancer cells with GnRH-Disorazol conjugates N2 - Das Ovarialkarzinom stellt einen häufigen maligen Tumor der Frau dar, der meist spät diagnostiziert wird. Therapeutische Optionen sind nur eingeschränkt verfügbar und nebenwirkungsbehaftet. In der modernen Tumortherapie sind zielgerichtete medikamentöse Ansätze von immer größer Bedeutung und sind bei verschiedenen Entitäten bereits zugelassen. Da Ovarialkarzinome häufig GnRH-Rezeptoren exprimieren, stellt dies einen guten Angriffspunkt für mögliche Therapeutika dar. In dieser Arbeit wurde die Wirkung von Disorazol, einem potenten Zytotoxin, in Kopplung an GnRH auf Ovarialkarzinom-Zellen untersucht. Unter anderem wurden hierbei RT-PCR, Kristallviolettversuche, WST-Versuche und FACS-Analysen durchgeführt. Molekularbiologisch war eine deutliche Expression von GnRH-Rezeptoren auf ovarialen Karzinomzellen zu sehen. Es zeigte sich eine spezifische Toxizität von GnRH-Disorazol-Konjugaten auf Ovarialkarzinom-Zelllinien und andere GnRH-tragende Zellen. Lymphozyten aus dem peripheren Blut waren nicht im besonderen Maße anfällig für Disorazol. Verapamil konnte in einzelnen Zelllinien die Toxizität des Konjugats verstärken, eine Cisplatin-Resistenz hatte jedoch keinen Einfluss darauf. Apoptose-inhibierende Substanzen wie zVAD verminderten den Anteil an toten Zellen, Necrostatin war dazu nicht in der Lage. Die spezifische Wirksamkeit von GnrH gekoppeltem Disorazol auf Ovarialkarzinomzellen bestätigt das ursprüngliche Therapiekonzept. Eine ausgeprägtere Hämatotoxizität konnte nicht nachgewiesen werden, was im Hinblick auf den klinischen Einsatz eine bedeutende Rolle spielt. Da einige weitere Entitäten wie das triple-negative Mamma-Karzinom GnRH-Rezeptor-exprimierende Zellen aufweisen, ist ein Einsatz auch in diesen Krankheitsbildern denkbar. N2 - Ovarian cancer is a frequent gynecological malignant disease with poor prognosis due to late diagnosis. Therapeutic options are limited. In modern oncologic treatment approaches, targeted therapy is a well-known therapeutic principle. Since ovarian cancer cells can express GnRH receptors, this can be used as a medical target. We investigated the toxic effect of conjugates consisting of Disorazol and GnRH on ovarian cancer cell lines. Among others RT-PCR, cristal violett assays, WST-assays and FACS-analysis were performed. RT-PCR revealed expression of the GnRH receptor in ovarian cancer cells. There was specific toxicity of GnRH-Disorazol-conjugates on cell lines representing ovarian cancer. In contrast, peripheral blood lymphocytes were not especially sensitive for Disorazol. Verapamil was able to enhance toxicity in distinct cell lines; Cisplatin resistant cell lines were sensitive for the conjugate too. Substances inhibiting apoptosis like z-VAD could decrease the amount of dead cells, whereas necrostatin had no effect. The specific toxicity of disorazol-GnRH-conjugates on ovarian cancer cells proofed the principle of this targeted therapy approach. Human lymphocytes were not especially sensitive to the toxin, which could play an important role with regard to the clinical use. Since other cancerous tissues like the triple negative breast cancer express GnRH receptors, this therapeutic approach could be reasonable in those entities. KW - Eierstockkrebs KW - Disorazole KW - Ovarialkarzinom KW - Disorazol KW - GnRH Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-219957 ER - TY - JOUR A1 - Glutsch, Valerie A1 - Grän, Franziska A1 - Weber, Judith A1 - Gesierich, Anja A1 - Goebeler, Matthias A1 - Schilling, Bastian T1 - Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy JF - Journal for ImmunoTherapy of Cancer N2 - Background High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined checkpoint inhibition. In BRAF wildtype patients with a primary resistance to PD-1 inhibitors, therapeutic options are therefore limited and immune-related adverse events (irAE) have to be taken into consideration when discussing a subsequent immunotherapy. Case presentation We report the case of a 68-year-old male patient with metastatic melanoma who experienced an acute renal failure with nephrotic syndrome due to a minimal change disease developing after a single dose of the anti-PD-1 antibody pembrolizumab. A kidney biopsy revealed a podocytopathy without signs of interstitial nephritis. Renal function recovered to almost normal creatinine and total urine protein levels upon treatment with oral steroids and diuretics. Unfortunately, a disease progression (PD, RECIST 1.1) was observed in a CT scan after resolution of the irAE. In a grand round, re-exposure to a PD-1-containing regime was recommended. Consensually, a combined immunotherapy with ipilimumab and nivolumab was initiated. Nephrotoxicity was tolerable during combined immunotherapy and a CT scan of chest and abdomen showed a deep partial remission (RECIST 1.1) after three doses of ipilimumab (3 mg/kg) and nivolumab (1 mg/kg). Conclusion This case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE. KW - PD-1 KW - Immune-related adverse event KW - Minimal change disease KW - Ipilimumab KW - Nivolumab Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201214 VL - 7 ER - TY - JOUR A1 - Rauschenberger, Tabea A1 - Schmitt, Viola A1 - Azeem, Muhammad A1 - Klein-Hessling, Stefan A1 - Murti, Krisna A1 - Grän, Franziska A1 - Goebeler, Matthias A1 - Kerstan, Andreas A1 - Klein, Matthias A1 - Bopp, Tobias A1 - Serfling, Edgar A1 - Muhammad, Khalid T1 - T cells control chemokine secretion by keratinocytes JF - Frontiers in Immunology N2 - The massive infiltration of lymphocytes into the skin is a hallmark of numerous human skin disorders. By co-culturing murine keratinocytes with splenic T cells we demonstrate here that T cells affect and control the synthesis and secretion of chemokines by keratinocytes. While pre-activated CD8\(^+\)T cells induce the synthesis of CXCL9 and CXCL10 in keratinocytes and keep in check the synthesis of CXCL1, CXCL5, and CCL20, keratinocytes dampen the synthesis of CCL3 and CCL4 in pre-activated CD8\(^+\)T cells. One key molecule is IFN-γ that is synthesized by CD8\(^+\)T cells under the control of NFATc1 and NFATc2. CD8\(^+\)T cells deficient for both NFAT factors are unable to induce CXCL9 and CXCL10 expression. In addition, CD8\(^+\)T cells induced numerous type I IFN-inducible “defense genes” in keratinocytes encoding the PD1 and CD40 ligands, TNF-α and caspase-1. The enhanced expression of type I IFN-inducible genes resembles the gene expression pattern at the dermal/epidermal interface in lichen planus, an inflammatory T lymphocyte-driven skin disease, in which we detected the expression of CXCL10 in keratinocytes in close vicinity to the infiltration front of T cells. These data reflect the multifaceted interplay of lymphocytes with keratinocytes at the molecular level. KW - chemokine KW - keratinocytes KW - IFN KW - lichen planus KW - T cells KW - Nfatc1 Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-195695 SN - 1664-3224 VL - 10 IS - 1917 ER -